{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T21:44:52Z","timestamp":1784843092843,"version":"3.55.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jdiacomp.2020.107830","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T02:28:43Z","timestamp":1609381723000},"page":"107830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of renin-angiotensin-aldosterone system inhibitors on all-cause mortality and major cardiovascular events in patients with diabetes: A meta-analysis focusing on the number needed to treat and minimal clinical effect"],"prefix":"10.1016","volume":"35","author":[{"given":"Xiao-Chun","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Li","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Jun","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuo-Ya","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruo-Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Xi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Bao","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2020.107830_bb0005","doi-asserted-by":"crossref","first-page":"850","DOI":"10.4239\/wjd.v6.i6.850","article-title":"Diabetes mellitus: the epidemic of the century","volume":"6","author":"Kharroubi","year":"2015","journal-title":"World J Diabetes"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0010","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.2337\/dc16-0614","article-title":"Risk of cause-specific death in individuals with diabetes: a competing risks analysis","volume":"39","author":"Baena-D\u00edez","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0015","unstructured":"World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva: Switzerland; 2009. Available at:Available from: <http:\/\/www.who.int\/healthinfo\/global_burden_disease\/GlobalHealthRisks_report_full.pdf>. Mar 28."},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0020","unstructured":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England). Nov 10 2018;392(10159):1789\u20131858."},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0025","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","article-title":"IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045","volume":"138","author":"Cho","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0030","series-title":"2018; Available from","article-title":"Deaths by cause, age, sex, by country and by region, 2000-2016","author":"Geneva, W.H.O. Global Health Estimates","year":"2016"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0035","unstructured":"Association, A.H. Cardiovascular Disease and Diabetes. 2015 [cited 2019 20 May 2019]; Available from: https:\/\/www.heart.org\/en\/health-topics\/diabetes\/why-diabetes-matters\/cardiovascular-disease--diabetes. ."},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0040","doi-asserted-by":"crossref","unstructured":"Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet (London, England) Jun 26 2010;375(9733):2215\u20132222. https:\/\/doi.org\/10.1016\/s0140-6736(10)60484-9.","DOI":"10.1016\/S0140-6736(10)60484-9"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2019.05.020","article-title":"The renin-angiotensin-aldosterone system and its therapeutic targets","volume":"186","author":"Mirabito Colafella","year":"2019","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0050","doi-asserted-by":"crossref","unstructured":"Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ (Clinical research ed). Oct 9 2004;329(7470):828. https:\/\/doi.org\/10.1136\/bmj.38237.585000.7C.","DOI":"10.1136\/bmj.38237.585000.7C"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0055","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","article-title":"Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients","volume":"33","author":"van Vark","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0060","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2012.10.011","article-title":"A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure","volume":"61","author":"Savarese","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0065","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis","volume":"174","author":"Cheng","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0070","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/HJH.0000000000000447","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs--overview and meta-analyses","volume":"33","author":"Thomopoulos","year":"2015","journal-title":"J Hypertens"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0075","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.mayocp.2015.10.019","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials","volume":"91","author":"Bangalore","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0080","doi-asserted-by":"crossref","unstructured":"Noordzij M, van Diepen M, Caskey FC, Jager KJ. Relative risk versus absolute risk: one cannot be interpreted without the other. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. Apr 1 2017;32(suppl_2):ii13-ii18. https:\/\/doi.org\/10.1093\/ndt\/gfw465.","DOI":"10.1093\/ndt\/gfw465"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0085","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ijcp.12142","article-title":"When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"67","author":"Citrome","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0090","doi-asserted-by":"crossref","unstructured":"Mendes D, Alves C, Batel-Marques F. Number needed to treat (NNT) in clinical literature: an appraisal. BMC medicine. Jun 1 2017;15(1):112. https:\/\/doi.org\/10.1186\/s12916-017-0875-8.","DOI":"10.1186\/s12916-017-0875-8"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0095","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/pds.3636","article-title":"Balancing benefit and risk of medicines: a systematic review and classification of available methodologies","volume":"23","author":"Mt-Isa","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0100","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1080\/14740338.2016.1217989","article-title":"Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons","volume":"15","author":"Mendes","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0105","unstructured":"BMJ. For Authors, Resources for Authors, Article Types, Research. bmj.com. http:\/\/www.bmj.com\/about-bmj\/resources-authors\/article-types\/research. Accessed 13 Oct 2016."},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0110","first-page":"c869","volume":"340","author":"Moher","year":"2010","journal-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials BMJ (Clinical research ed)"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0115","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jclinepi.2015.11.002","article-title":"Systematic reviews experience major limitations in reporting absolute effects","volume":"72","author":"Alonso-Coello","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0120","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1001\/jama.287.21.2813","article-title":"Reporting number needed to treat and absolute risk reduction in randomized controlled trials","volume":"287","author":"Nuovo","year":"2002","journal-title":"Jama."},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0125","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2288-9-21","article-title":"Calculation of NNTs in RCTs with time-to-event outcomes: a literature review","volume":"9","author":"Hildebrandt","year":"2009","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0130","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s40263-016-0377-9","article-title":"Benefit-risk of therapies for relapsing-remitting multiple sclerosis: testing the number needed to treat to benefit (NNTB), number needed to treat to harm (NNTH) and the likelihood to be helped or harmed (LHH): a systematic review and meta-analysis","volume":"30","author":"Mendes","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0135","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1600-0447.2009.01449.x","article-title":"Relative vs. absolute measures of benefit and risk: what\u2019s the difference?","volume":"121","author":"Citrome","year":"2010","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0140","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1475-6773.2005.0k375.x","article-title":"Commentary--goodbye M(C)ID! Hello MID, where do you come from?","volume":"40","author":"Sch\u00fcnemann","year":"2005","journal-title":"Health Serv Res"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0145","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-007953","article-title":"Minimally important difference estimates and methods: a protocol","volume":"5","author":"Johnston","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0150","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jclinepi.2019.03.007","article-title":"The number needed to treat in pairwise and network meta-analysis and its graphical representation","volume":"111","author":"Veroniki","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0155","doi-asserted-by":"crossref","unstructured":"Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. The New England journal of medicine. Jun 30 1988;318(26):1728\u20131733. doi:10.1056\/nejm198806303182605.","DOI":"10.1056\/NEJM198806303182605"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0160","series-title":"Clinical Epidemiology:A Basic Science for Clinical Medicine","volume":"Vol. 208","author":"Sackett","year":"1991"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0165","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1046\/j.1525-1497.2002.11111.x","article-title":"Determination of the clinical importance of study results","volume":"17","author":"Man-Son-Hing","year":"2002","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0170","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022839","article-title":"Utility of the number needed to treat in paediatric haematological cancer randomised controlled treatment trials: a systematic review","volume":"9","author":"Hasan","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0175","doi-asserted-by":"crossref","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. The New England journal of medicine. Nov 11 1993;329(20):1456\u20131462. doi:10.1056\/nejm199311113292004.","DOI":"10.1056\/NEJM199311113292004"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0180","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0735-1097(99)00146-1","article-title":"Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction","volume":"34","author":"Gustafsson","year":"1999","journal-title":"Trace Study Group. Journal of the American College of Cardiology"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0185","doi-asserted-by":"crossref","unstructured":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet (London, England). Jan 22 2000;355(9200):253\u2013259.","DOI":"10.1016\/S0140-6736(99)12323-7"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0190","doi-asserted-by":"crossref","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England journal of medicine. Sep 20 2001;345(12):861\u2013869. https:\/\/doi.org\/10.1056\/NEJMoa011161.","DOI":"10.1056\/NEJMoa011161"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0195","doi-asserted-by":"crossref","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. The New England journal of medicine. Sep 20 2001;345(12):851\u2013860. https:\/\/doi.org\/10.1056\/NEJMoa011303.","DOI":"10.1056\/NEJMoa011303"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0200","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/08037050410029605","article-title":"Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial","volume":"13","author":"Berthet","year":"2004","journal-title":"Blood Press"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0205","doi-asserted-by":"crossref","unstructured":"Marre M, Lievre M, Chatellier G, Mann JF, Passa P, M\u00e9nard J. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ (Clinical research ed). Feb 28 2004;328(7438):495. https:\/\/doi.org\/10.1136\/bmj.37970.629537.0D.","DOI":"10.1136\/bmj.37970.629537.0D"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0210","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/eurheartj\/ehi225","article-title":"The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy","volume":"26","author":"Daly","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0215","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/08037050510008823","article-title":"The study on COgnition and prognosis in the elderly (SCOPE) - major CV events and stroke in subgroups of patients","volume":"14","author":"Trenkwalder","year":"2005","journal-title":"Blood Press"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0220","doi-asserted-by":"crossref","unstructured":"Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. The New England journal of medicine. Sep 18 2008;359(12):1225\u20131237. https:\/\/doi.org\/10.1056\/NEJMoa0804593.","DOI":"10.1056\/NEJMoa0804593"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0225","doi-asserted-by":"crossref","unstructured":"Bilous R, Chaturvedi N, Sj\u00f8lie AK, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Annals of internal medicine. Jul 7 2009;151(1):11\u201320, w13\u201314. doi:10.7326\/0003-4819-151-1-200907070\u201300120.","DOI":"10.7326\/0003-4819-151-1-200907070-00120"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0230","doi-asserted-by":"crossref","unstructured":"Haller H, Ito S, Izzo JL, Jr., et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. The New England journal of medicine. Mar 10 2011;364(10):907\u2013917. https:\/\/doi.org\/10.1056\/NEJMoa1007994.","DOI":"10.1056\/NEJMoa1007994"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0235","doi-asserted-by":"crossref","unstructured":"Ruggenenti P, Lauria G, Iliev IP, et al. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension (Dallas, Tex : 1979). Nov 2011;58(5):776\u2013783. https:\/\/doi.org\/10.1161\/hypertensionaha.111.174474.","DOI":"10.1161\/HYPERTENSIONAHA.111.174474"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0240","doi-asserted-by":"crossref","unstructured":"Imai E, Haneda M, Yamasaki T, et al. Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension). Hypertension research : official journal of the Japanese Society of Hypertension. Dec 2013;36(12):1051\u20131059. https:\/\/doi.org\/10.1038\/hr.2013.86.","DOI":"10.1038\/hr.2013.86"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0245","doi-asserted-by":"crossref","unstructured":"Chalmers J, Arima H, Woodward M, et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension (Dallas, Tex : 1979). Feb 2014;63(2):259\u2013264. https:\/\/doi.org\/10.1161\/hypertensionaha.113.02252.","DOI":"10.1161\/HYPERTENSIONAHA.113.02252"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001971","article-title":"Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses","volume":"13","author":"Catal\u00e1-L\u00f3pez","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0255","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1586\/erc.13.42","article-title":"The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review","volume":"11","author":"Ferrari","year":"2013","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0260","doi-asserted-by":"crossref","unstructured":"Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. Aug 22 2006;114(8):838\u2013854. https:\/\/doi.org\/10.1161\/circulationaha.105.594986.","DOI":"10.1161\/CIRCULATIONAHA.105.594986"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0265","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.pcad.2015.11.004","article-title":"The divergent cardiovascular effects of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on myocardial infarction and death","volume":"58","author":"Strauss","year":"2016","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jdiacomp.2020.107830_bb0270","doi-asserted-by":"crossref","unstructured":"Strauss MH, Hall AS. Angiotensin Receptor Blockers Do Not Reduce Risk of Myocardial Infarction, Cardiovascular Death, or Total Mortality: Further Evidence for the ARB-MI Paradox. Circulation. May 30 2017;135(22):2088\u20132090. https:\/\/doi.org\/10.1161\/circulationaha.117.026112.","DOI":"10.1161\/CIRCULATIONAHA.117.026112"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872720306310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872720306310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:14:37Z","timestamp":1761005677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872720306310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1056872720306310"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107830","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of renin-angiotensin-aldosterone system inhibitors on all-cause mortality and major cardiovascular events in patients with diabetes: A meta-analysis focusing on the number needed to treat and minimal clinical effect","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107830","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107830"}}